Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gabexate→

Gabexate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
39492-01-8
Molecular formula
C16H23N3O4
Molecular weight
321.37 g/mol
Drug class
Synthetic serine protease inhibitoranticoagulant and protease-modulating agent
Mechanism of action
A rapidly hydrolysed synthetic serine protease inhibitor that inhibits thrombin, plasmin and kallikrein, limiting proteolysis and aspects of coagulation and fibrinolysis. It does not inhibit all serine proteases, and activity is short-lived because of rapid plasma metabolism.
Indications / reported uses
  • Treatment of acute pancreatitis and disseminated intravascular coagulation in countries where gabexate mesilate is authorised.
  • Regional anticoagulation during haemodialysis in selected settings, according to local practice and product authorisation.

Sources: https://www.ncbi.nlm.nih.gov/mesh?term=Gabexate · https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7863 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Gabexate Environmental Risk Assessment (ERA) (the Gabexate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.